文献速递淋巴瘤

最大肿瘤直径与局限期霍奇金淋巴瘤复发风险相关:一项国际研究

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.
PubMed 文献 · Blood Adv · 2025-01-01

该国际研究在H10试验中外部验证RAPID试验发现,即最大肿瘤直径(MTD)与局限期霍奇金淋巴瘤(LS-HL)患者达到PET阴性后的复发风险相关。H10中MTD与无事件生存强相关(HR 1.22,95%CI 1.07-1.38,P=0.003),与RAPID相似(HR 1.19,95%CI 1.02-1.39,P=0.02),合并HR 1.21(95%CI 1.09-1.33,P<0.001),每厘米MTD估计风险增加21%。单纯ABVD与ABVD联合放疗的效果相似,无差异效应(交互作用P=0.97)。

要点

  • 在达到PET阴性的局限期霍奇金淋巴瘤患者中,最大肿瘤直径与复发风险强相关。
  • H10试验中MTD的HR为1.22(95%CI 1.07-1.38,P=0.003),RAPID试验中为1.19(95%CI 1.02-1.39,P=0.02)。
  • 合并HR为1.21(95%CI 1.09-1.33,P<0.001),估计每厘米MTD风险增加21%。

核心结论

  • 该国际验证研究证实,在达到PET阴性的局限期霍奇金淋巴瘤患者中,最大肿瘤直径与复发风险强相关,并有助于围绕风险适配的放疗应用进行决策。

研究设计与样本

  • 国际验证研究,纳入H10试验中I/IIA期、无纵隔巨块、经ABVD达到PET阴性的霍奇金淋巴瘤患者,并对比RAPID试验数据。
  • RAPID试验中患者接受3周期ABVD联合放疗(n=208)或3周期ABVD alone(n=211)。
  • H10试验中患者接受3至4周期ABVD联合放疗(n=556)或4至6周期ABVD alone(n=303)。

主要发现

  • H10试验中MTD与无事件生存(复发或HL相关死亡)强相关,HR为1.22(95%CI 1.07-1.38,P=0.003)。
  • RAPID试验中MTD与无事件生存的关联相似,HR为1.19(95%CI 1.02-1.39,P=0.02)。
  • 合并估计每厘米MTD风险增加21%(HRpooled 1.21,95%CI 1.09-1.33,P<0.001)。
  • 单纯ABVD与ABVD联合放疗患者的效应大小相似,无差异效应(交互作用P=0.97)。
  • 治疗方式和MTD为独立风险因素;MTD较高且接受单纯化疗的患者复发风险最大。

临床怎么用

  • 原文结论指出,该研究结果有助于围绕风险适配的放疗应用进行决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor bulk is an established prognostic factor in Hodgkin lymphoma (HL), but most patients with limited-stage (LS) HL do not have "bulk" by standard definitions. In the RAPID trial, maximum tumor diameter (MTD) was associated with relapse risk in LS-HL patients achieving positron emission tomography negativity (PET-) after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). We aimed to externally validate these findings in the H10 trial. Stage I/IIA HL patients, without mediastinal bulk, who achieved PET- with ABVD were included. Patients received 3 ABVD plus radiotherapy (n = 208) or 3 ABVD alone (n = 211) in RAPID, and 3 to 4 ABVD plus radiotherapy (n = 556) or 4 to 6 ABVD alone (n = 303) in H10. MTD was strongly associated with event-free survival (relapse or HL-related death) in H10 (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.07-1.38; P = .003), a similar effect to that seen in RAPID (HR, 1.19; 95% CI, 1.02-1.39; P = .02), giving an estimated 21% risk increase per centimeter MTD (HRpooled, 1.21; 95% CI, 1.09-1.33; P < .001). Effect sizes were similar for patients treated with ABVD alone and ABVD plus radiotherapy, with no differential effect (pinteraction = 0.97). Treatment modality and MTD were independent risk factors; patients with higher MTD receiving chemotherapy alone had the greatest relapse risk. This international validation study confirms MTD is strongly associated with relapse risk in patients with LS-HL achieving PET- and informs decision-making around risk-adapted application of radiotherapy. The trials were registered at www.clinicaltrials.gov as #NCT00943423 and #NCT00433433.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Phillips EH, Counsell N, Illidge T, et al. Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study. Blood Adv. 2025. PMID: 39774828. doi:10.1182/bloodadvances.2024015140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。